US20060073128A1 - Means and methods for the modulation of arteriogenesis - Google Patents
Means and methods for the modulation of arteriogenesis Download PDFInfo
- Publication number
- US20060073128A1 US20060073128A1 US11/252,623 US25262305A US2006073128A1 US 20060073128 A1 US20060073128 A1 US 20060073128A1 US 25262305 A US25262305 A US 25262305A US 2006073128 A1 US2006073128 A1 US 2006073128A1
- Authority
- US
- United States
- Prior art keywords
- tgfβ1
- arteries
- collateral
- arteriogenesis
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 62
- 230000027746 artery morphogenesis Effects 0.000 title claims abstract description 30
- 210000001367 artery Anatomy 0.000 claims abstract description 67
- 230000012010 growth Effects 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 210000000056 organ Anatomy 0.000 claims abstract description 13
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims abstract description 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims abstract description 8
- 230000002708 enhancing effect Effects 0.000 claims abstract description 7
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 239000003102 growth factor Substances 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 206010062542 Arterial insufficiency Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000009278 visceral effect Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 1
- 208000015670 renal artery disease Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 abstract description 32
- 102000039446 nucleic acids Human genes 0.000 abstract description 30
- 108020004707 nucleic acids Proteins 0.000 abstract description 30
- 238000011282 treatment Methods 0.000 abstract description 18
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 230000004071 biological effect Effects 0.000 abstract description 13
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 35
- 210000001616 monocyte Anatomy 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 21
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 210000002540 macrophage Anatomy 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 210000002889 endothelial cell Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000000816 peptidomimetic Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 210000001105 femoral artery Anatomy 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 6
- 206010069729 Collateral circulation Diseases 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000007374 Smad Proteins Human genes 0.000 description 5
- 108010007945 Smad Proteins Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 102000019997 adhesion receptor Human genes 0.000 description 4
- 108010013985 adhesion receptor Proteins 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 230000001889 chemoattractive effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000001623 arteriogenic effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000006467 collateral growth Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 2
- 101000962498 Macropis fulvipes Macropin Proteins 0.000 description 2
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 2
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150094949 APRT gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000036376 Femoral artery occlusion Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229940122060 Ornithine decarboxylase inhibitor Drugs 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002818 ornithine decarboxylase inhibitor Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- -1 polymethylene units Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 101150111232 trpB-1 gene Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar connections.
- the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an organ, tissue or cells with transforming growth factor beta 1 (TGF ⁇ 1) or a nucleic acid molecule encoding TGF ⁇ 1.
- TGF ⁇ 1 transforming growth factor beta 1
- the present invention also relates to the use of TGF ⁇ 1 or a nucleic acid molecule encoding TGF ⁇ 1 for the preparation of pharmaceutical compositions for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
- the present invention relates to a method for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF ⁇ 1.
- the present invention further involves the use of an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF ⁇ 1 for the preparation of pharmaceutical compositions for the treatment of tumors.
- vascular growth in adult organisms proceeds via two distinct mechanisms, sprouting of capillaries (angiogenesis) and in situ enlargement of preexisting arteriolar connections into true collateral arteries (Schaper, J. Collateral Circulation—Heart, Brain, Kidney, Limbs. Boston, Dordrecht, London: Kluwer Academic Publishers; 1993).
- VEGF vascular endothelial growth factor
- Recent studies have disclosed mechanisms leading to angiogenesis with vascular endothelial growth factor (VEGF) as a major component (Tuder, J. Clin. Invest. 95 (1995), 1798-1807; Plate, Nature 359 (1992), 845-848; Ferrara, Endocrine Reviews 13 (1992), 18-42; Klagsbrun, Annu. Rev. Physiol.
- agents such as VEGF and other growth factors are presently being employed to stimulate the development of angiogenesis after arterial occlusion, such agents are not envisaged as being capable of modulating the growth of preexisting arteriolar connections into true collateral arteries.
- the technical problem of the present invention is to provide means and methods for the modulation of arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
- the present invention is a method for enhancing arteriogenesis and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with transforming growth factor beta 1 (TGF ⁇ 1) and/or a nucleic acid molecule encoding said TGF ⁇ 1.
- TGF ⁇ 1 transforming growth factor beta 1
- TGF ⁇ 1 refers to proteins and peptides which act on macrophages and which are capable of promoting collateral artery growth by direct activation, proliferation and/or potentiation of the effector functions of resident and newly recited macrophages on blood vessels.
- the present invention also comprises substances which are functionally equivalent to TGF ⁇ 1 in that these substances are capable of electing the aforementioned biological responses.
- the action of the TGF ⁇ 1 employed in the present invention may not be limited to the above-described specificity but they may also act on, for example eosinophils, lymphocyte subpopulations and/or stem cells.
- TGF- ⁇ 1 The in-vivo arteriogenic effects of TGF- ⁇ 1 , observed in accordance with the present invention are caused by activation of monocytes, leading to an increased adhesion, migration and subsequently perivascular accumulation of monocytes/macrophages. It has been found in accordance with the invention that said adhesion is inter alia due to increased expression of the adhesion receptor Mac-1. Adhesion and transmigration of monocytes/macrophages are initial steps in the process of arteriogenesis. In a further step production of various growth factors, such as basic-fibroblast growth factor (b-FGF), Platlet derived growth factor (PDGF).
- b-FGF basic-fibroblast growth factor
- PDGF Platlet derived growth factor
- TGFa tumor necrosisi factor alpha
- II-1 Interleukine 1
- IL-6 Interleukine 6
- VEGF vascular endothelial growth factor
- TGF- ⁇ 1 direct stimulation of vascular smooth muscle cells and/or endothelial cells by TGF- ⁇ 1 .
- arteriogenesis is further influenced by TGF- ⁇ 1 due to the direct stimulation of the vascular smooth muscle cells and/or the endothelial cells in accordance with the present invention.
- TGF- ⁇ 1 is a third specific arteriogenic substance, next to MCP-1 and the aforementioned CSFs, acting via the monocytic pathway, wherein TGF- ⁇ 1 , increases arteriogenesis via activation of monocytes and induction of MAC-1 expression.
- macrophages/monocytes can be efficiently activated by TGF ⁇ 1 and can subsequently adhere due to the upregulation of Mac-1 expression. Thereby, arteriogenesis via the macrophage/monocyte pathway is initiated and can be efficiently simulated in vivo.
- TGF ⁇ 1 to be employed in the methods and uses of the present invention may be obtained from various sources described in the prior art; see, e.g., Klagsbrun, Annu. Rev. Physiol. 53 (1991), 217-239.
- functional equivalent or “functional part” of TGF ⁇ 1 means a protein having part or all of the primary structural conformation of TGF ⁇ 1 possessing at least the biological property of promoting at least one macrophage or granulocyte effector function mentioned above.
- the functional part of said protein or the functionally equivalent protein may be a derivative by way of amino acid deletion(s), substitution(s), insertion(s), addition(s) and/or replacement(s) of the amino acid sequence, for example by means of site directed mutagenesis of the underlying. DNA.
- Recombinant DNA technology is well known to those skilled in the art and described, for example, in Sambrook et al. (Molecular cloning; A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y. (1989)). Modified CSFs art described, e.g., in Yamasaki, Journal of Biochemistry 115 (1994), 814-819.
- TGF ⁇ 1 or functional parts thereof or proteins which are functionally equivalent thereto may be produced by known conventional chemical syntheses or recombinant techniques employing the amino acid and DNA sequences described in the prior art; see, e.g., EP-A-0 177 568; Han, Source Gene 175 (1996), 101-104; Kothari, Blood Cells, Molecules & Diseases 21 (1995), 192-200; Holloway. European Journal of Cancer 30A (1994), 2-6.
- TGF ⁇ 1 may be produced by culturing a suitable cell or cell line which has been transformed with a DNA sequence encoding upon expression under the control of regulatory sequences TGF ⁇ 1 or a functional part thereof or a protein which is functionally equivalent TGF ⁇ 1.
- TGF ⁇ 1 and proteins as described above useful in the methods and uses of the present invention by chemical synthetic means are also known to those of skill in the art.
- the invention relates to the use of transforming growth factor beta 1 (TGF ⁇ 1) and/or a nucleic acid molecule encoding said T TGF ⁇ 1 for the preparation of a pharmaceutical composition for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
- TGF ⁇ 1 transforming growth factor beta 1
- nucleic acid molecule encoding said T TGF ⁇ 1 for the preparation of a pharmaceutical composition for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
- the pharmaceutical composition comprises at least TGF ⁇ 1 as defined above, and optionally a pharmaceutically acceptable carrier or exipient.
- suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.
- Compositions comprising such carriers can be formulated by conventional methods.
- the pharmaceutical compositions can be administered to the subject at a suitable dose.
- the dosage regimen may be determined by the attending physician considering the condition of the patient, the severity of the disease and other clinical factors.
- Administration of the suitable compositions may be effected by different ways, e.g. by intravenous, intraperetoneal, subcutaneous, intramuscular, topical or intradermal administration.
- the dosage regimen will be determined by the attending physician and other clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Generally, the regimen as a regular administration of the pharmaceutical composition should be in the range of 1 ⁇ g to 10 mg units per day. If the regimen is a continuous infusion, it should also be in the range of 1 ⁇ g to 10 mg units per kilogram of body weight per minute, respectively. Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 10 6 to 10 12 copies of the DNA molecule.
- compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery.
- TGF ⁇ 1 used in the methods and uses of the invention is a recombinant TGF ⁇ 1.
- DNA sequences for TGF ⁇ 1 which can be applied in the methods and uses of the invention are known in the prior art and described in e.g. Ohta, Biochem. J. 350 (2000), 395-404.
- DNA and amino acid sequences of TGF ⁇ 1 are available in the Gene Bank database.
- methods for the production of recombinant proteins are well-known to the person skilled in the art; see, e.g., Sambrook, supra.
- the method and the use of the present invention is designed to be applied in conjugation with a growth factor or cytokine comprising fibroblast growth factor (FGF), preferably b-FGF, platelet derived growth factor (PDGF), tumor necrosis Factor alpha (TNF ⁇ ), interleukin 1 (IL-1), Interleukin 6 (IL-6), or vascular endothelial growth factor (VEGF).
- FGF fibroblast growth factor
- PDGF platelet derived growth factor
- TNF ⁇ tumor necrosis Factor alpha
- IL-1 interleukin 1
- IL-6 Interleukin 6
- VEGF vascular endothelial growth factor
- This embodiment is particularly suited for enhancing of both sprouting of capillaries (angiogenesis) and in situ enlargement of preexisting arteriolar connections into true collateral arteries.
- Pharmaceutical compositions comprising TGF ⁇ 1, and a growth factor such as VEGF may be used for the treatment of peripheral vascular diseases or coronary artery disease.
- nucleic acid and amino acid sequences of said growth factors or cytokines are well known in the art and are available e.g. in the GeneBank database.
- the method of the invention comprises
- the TGF ⁇ 1 and the nucleic acid molecules encoding said proteins are administered either alone or in combination, and optionally together with a pharmaceutically acceptable carrier or exipient.
- Said nucleic acid molecules may be stably integrated into the genome of the cell or may be maintained in a form extrachromosomally, see, e.g., Calos, Trends Genet. 12 (1996), 463-466.
- viral vectors described in the prior art may be used for transfecting certain cells, tissues or organs.
- a pharmaceutical composition of the invention which comprises a nucleic acid molecule encoding TGF ⁇ 1 in gene therapy.
- Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, r naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses, and adeno-associated viruses, among others. Delivery of nucleic acid molecules to a specific site in the body for gene therapy may also be accomplished using a biolistic delivery system, such as that described by Williams (Proc. Nati. Acad. Sci. USA 88 (1991), 2726-2729).
- Standard methods for transfecting cells with nucleic acid molecules are well known r to those skilled in the art of molecular biology, see, e.g., WO 94/29469.
- Gene therapy to prevent or decrease the development of diseases described herein may be carried out by directly administering the nucleic acid molecule encoding TGF ⁇ 1 to r a patient or by transfecting cells with said nucleic acid molecule ex vivo and infusing the transfected cells into the patient.
- research pertaining to gene transfer into cells of the germ line is one of the fastest growing fields in reproductive biology.
- Gene therapy which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer.
- Suitable vectors and methods for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in, the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Isner, Lancet 348 (1996). 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Wang, Nature Medicine 2 (1996), 714-716; W094/29469; WO 97/00957 or Schaper, Current Opinion in Biotechnology 7 (1996), 635-640, and references cited therein.
- the nucleic acid molecules comprised in the pharmaceutical composition of the invention may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) containing said nucleic acid molecule into the cell.
- said cell is a germ line cell, embryonic cell, or egg cell or derived therefrom.
- the introduced nucleic acid molecules encoding the TGF ⁇ 1 express said proteins after introduction into said cell and preferably remain in this status during the lifetime of said cell.
- cell lines which stably express said TGF ⁇ 1 may be engineered according to methods well known to those skilled in the art. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with the recombinant DNA molecule or vector of the invention and a selectable marker, either on the same or separate vectors. Following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
- the selectable marker in the recombinant plasmid confers resistance to the selection and allows for the selection of cells having stably integrated the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.
- This method may advantageously be used to engineer cell lines which express TGF ⁇ 1.
- Such cells may be also be administered in accordance with the pharmaceutical compositions, methods and uses of the invention.
- a number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, Cell 11 (1977), 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska, Proc. Natl. Acad. Sci. USA 48 (1962). 2026), and adenine phosphoribosyltransferase (Lowy, Cell 22 (1980), 817) in tk_. hgprt or aprt cells, respectively.
- antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, Proc. Nati. Acad. Sci.
- trpB which allows cells to utilize indole in place of tryptophan
- hisD which allows cells to utilize histinol in place of histidine
- ODC ornithine decarboxylase
- DFMO 2-(difluoromethyl)-DL-ornithine
- the nucleic acid molecule comprised in the pharmaceutical composition for the use of the invention is designed for the expression of TGF ⁇ 1 by cells in vivo by, for example, direct introduction of said nucleic acid, molecule or introduction of a plasmid, a plasmid in liposomes, or a viral vector (e.g. adenoviral, retroviral) containing said nucleic acid molecule.
- a viral vector e.g. adenoviral, retroviral
- the TGF ⁇ 1 derivative or functional equivalent substance is an antibody, (poly)peptide, nucleic acid, small organic compound, ligand, hormone, PNA or peptidomimetic.
- TGF ⁇ 1 to be employed according to the present invention may be, e.g., modified by conventional methods known in the art.
- fragments which retain the biological activity of TGF ⁇ 1 as k described above, namely the capability of promoting collateral artery growth.
- This further allows the construction of chimeric proteins and peptides wherein other functional amino acid sequences may be either physically linked by, e.g., chemical means to TGF ⁇ 1 or may be fused by recombinant DNA techniques well known in the art.
- folding simulations and computer redesign of structural motifs of the C TGF ⁇ 1 as well as their respective receptors can be performed using appropriate computer programs (Olszewski, Proteins 25 (1996), 286-299; Hoffman, Comput. Appl. 11 Biosci. 11 (1995), 675-679).
- Computer modeling of protein folding can be used for the conformational and energetic analysis of detailed receptor and protein models (Monge, J. Mol. Biol. 247 (1995), 995-1012; Renouf, Adv. Exp. Med. Biol. 376 (1995), 37-45).
- the appropriate programs can be used for the identification of interactive sites of TGF ⁇ 1 and their respective receptors by computer assistant searches for complementary peptide sequences (Fassina, Immunomethods 5 (1994), 114-120). Further appropriate computer systems for the design of protein and peptides are described in the prior art, for example in Berry, Biochem. Soc. Trans. 22 (1994), 10331036; Wodak, Ann. N. Y. Acad. Sci. 501 (1987), 1-13; Pabo, Biochemistry 25 (1986), 5987-5991. The results obtained from the above-described computer analysis can be used for, e.g., the preparation of peptidomimetics of TGF ⁇ 1, or fragments thereof.
- Such pseudopeptide analogues of the natural amino acid sequence of the protein may very efficiently mimic the parent protein or peptide (Benkirane, J. Biol. Chem. 271 (1996), 33218-33224).
- incorporation of easily available achiral Q-amino acid residues into TGF ⁇ 1 protein or a fragment thereof results in the substitution of amide bonds by polymethylene units of an aliphatic chain, thereby providing a convenient strategy for constructing a peptidomimetic (Banerjee, Biopolymers 39 (1996), 769-777).
- Superactive peptidomimetic analogues of small peptide hormones in other systems are described in the prior art (Zhang, Biochem. Biophys. Res. Commun.
- peptidomimetics may also be identified by the synthesis of peptidomimetic combinatorial libraries through successive amide alkylation and testing the resulting compounds, e.g., according to the methods described in the prior art. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, Methods in Enzymology 267 (1996), 220-234 and Domer, Bioorg. Med. Chem. 4 (1996), 709-715. Furthermore, antibodies or fragments thereof may be employed which, e.g., upon binding to a TGF ⁇ 1-receptor mimic the biological activity of the receptor's ligand.
- a three-dimensional and/or crystallographic structure of the TGF ⁇ 1 or of its receptors can be used for the design of peptidomimetic inhibitors of the biological activity of a CSF (Rose, Biochemistry 35 (1996), 12933-12944; Rutenbar, Bioorg. Med. Chem. 4 (1996), 1545-1558).
- the methods and uses of the invention may be employed for diseases caused by a vascular disease or a cardiac infarct or a stroke or for any disease where an increase of blood supply via collaterals, arteries etc. is needed.
- the methods and uses of the invention are designed to be applied to a subject suffering from arteriosclerosis, a coronary artery disease, a cerebral occlusive disease, a peripheral occlusive disease, a visceral occlusive disease, renal occlusive disease, a mesenterial arterial insufficiency or an ophthamic or retenal occlusion or for any disease where atherosclerotic plaques in the vascular wall lead to an obstruction of the vessel diameter.
- the methods and uses of the invention are designed to be applied to a subject during or after exposure to an agent or radiation or surgical treatment which damage or destroy arteries.
- arteriogenesis and the growth of arteries from preexisting arteriolar connections is essential for the delivery of nutrition to tumors.
- the growth of said vessels to the tumor would be suppressed suppression and/or inhibition of tumor growth is to be expected.
- the invention relates to a method for the treatment of tumors comprising contacting organs, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections though inhibition of the biological activity of TGF ⁇ 1 as defined above.
- TGF ⁇ 1 stimulates macrophages/monocytes and increases adhesion of said cells to the enothelial cells of the blood vessels inter alia via increased expression of the adhesion receptor Mac-1.
- Transmigration and adhesion to the endothelial cells are the initial steps of arteriogenesis as occurs during tumor formation.
- growth factors and cytokines comprising those referred to herein above are released due to said stimulation of the macrophages/monocytes by TGF ⁇ 1.
- TGF ⁇ 1 as a trigger molecule in accordance with the present invention it is now possible to treat tumor diseases caused or influenced by arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections by the methods and uses referred to herein above and below.
- the invention relates to the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF ⁇ 1 as defined above for the preparation of a pharmaceutical composition for the treatment of tumors.
- the agent inhibits the biological activity of TGF ⁇ 1 and/or inhibits an intracellular signal or signal cascade comprising SMAD proteins triggered in macrophages through the receptor for TGF ⁇ 1.
- SMAD proteins used in accordance with the present invention refers to a family of signal transducers and transcription factors which are activated intracellularly by the TGFP receptors upon stimulation by TGF ⁇ 1. These signal transducers are either directly or indirectly involved in the activation of TGF ⁇ 1 target genes and hence in elicting a biological response. Thus, the expression of growth factors or Mac1 protein may be stimulated and/or induced by said SMAD proteins.
- An agent which inhibits the biological activity of TGF ⁇ 1 also inhibits the intracellular i transducing of the signal by SMAD proteins upon binding of TGF ⁇ 1 to its receptor on target cells.
- SMAD proteins are well known in the art. Nucleic acid or amino acid sequences are available, e.g., in the database GeneBank. Moreover, it has been reported that blood vessels are a pivotal expression site of said SMAD proteins in the developing mouse embryo (Dick, Developmental Dynamics, 211 (1998), 293-305).
- the agent blocks interaction of TGF ⁇ 1 and its receptor.
- Receptors for TGF ⁇ 1 are well known in the art and have been described in, e.g., Lin et al., Mol. Reprod. Dev. 32 (1992), 105-110; Nilsen-Hamilton et al., New Biol. 4 (1992), 127-131. Moreover, amino acid and nucleic acid sequences are provided by the Gene Bank database.
- the agent used in the methods and uses of the invention is a(n) antibody, (poly)peptide, nucleic acid, small organic compound, ligand, hormone, PNA or peptidomimetic.
- Nucleic acid molecules specifically hybridizing to TGF ⁇ 1 encoding genes and/or their regulatory sequences may be used for repression of expression of said gene, for example due to an antisense or triple helix effect or they may be used for the construction of appropriate ribozymes (see, e.g., EP-B1 0 291 533, EP-A1 0 321 201, EP-A2 0 360 257) which specifically cleave the (pre)-mRNA of a gene encoding a CSF.
- TGF ⁇ 1 The nucleic and amino acid sequences encoding TGF ⁇ 1 are known in the art and described, for example, in Han, Source Gene 175 (1996), 101-104; Kothari, Blood Cells, Molecules & Diseases 21 (1995), 192-200 or in Holloway, European Journal of Cancer 30A (1994), 2-6. Selection of appropriate target sites and corresponding ribozymes can be done as described for example in Steinecke, Ribozymes, Methods in Cell Biology 50, Galbraith et al. eds Academic Press, Inc. (1995), 449-460.
- Nucleic acids comprise DNA or RNA or hybrids thereof. Furthermore, said nucleic acid may contain, for example, thioester bonds and/or nucleotide analogues, commonly used in oligonucleotide anti-sense approaches. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell. Furthermore, the so-called “peptide nucleic acid” (PNA) technique can be used for the inhibition of the expression of a gene encoding a TGF ⁇ 1.
- PNA peptide nucleic acid
- PNAs binding of PNAs to complementary as well as various single stranded RNA and DNA nucleic acid molecules can be systematically investigated using, e.g., thermal denaturation and BlAcore surface-interaction techniques (Jensen, Biochemistry 36 (1997), 5072-5077).
- the synthesis of PNAs can be performed, according to methods known in the art, for example, as described in Koch, J. Pept. Res. 49 (1997), 80-88; Finn, Nucleic Acids Research 24 (1996), 3357-3363, TGF ⁇ 1 and its receptor can be performed as described above to design drugs capable of inhibiting the biological activity of TGF ⁇ 1.
- antibodies may be employed specifically recognizing TGF ⁇ 1 or its j receptor or parts, i.e. specific fragments or epitopes, of TGF ⁇ 1 and its receptor thereby j inactivating the TGF ⁇ 1 or its receptor.
- These antibodies can be monoclonal antibodies, polyclonal antibodies or synthetic antibodies as well as fragments of antibodies, such as Fab, Fv or scFv fragments etc.
- Antibodies or fragments thereof can be obtained by using methods which are described, e.g., in Harlow and Lane “Antibodies, A Laboratory Manual”, CSH Press, Cold Spring Harbor, 1988 or EP-B1 0 451 216 and references cited therein.
- surface plasmon resonance as employed in the BlAcore system can be used to increase the efficiency of phage antibodies which bind to an epitope of TGF ⁇ 1 or its receptor (Schier, Human I Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13).
- Putative inhibitors which can be used in accordance with the present invention including peptides, proteins, nucleic acids, antibodies, small organic compounds, ligands, hormones, peptidomimetics, PNAs and the like capable of inhibiting the biological activity of TGF ⁇ 1 or its receptor may be identified according to the methods known in the art, for example as described in EP-A-O 403 506 or in the appended examples.
- a tumor which is a vascular tumor, preferably selected from the group consisting of Colon Carcinoma, Sarcoma, Carcinoma in the breast, Carcinoma in the head/neck, Mesothelioma, Glioblastoma, Lymphoma and Meningeoma.
- the pharmaceutical composition in the use of the invention is designed for administration by catheter intraarterial, intravenous, intraperitoneal or subcutenous routes.
- the TGF ⁇ 1 protein was for instance administered locally via osmotic minipump.
- the use and methods of the invention can be used for the treatment of all kinds of diseases hitherto unknown as being related to or dependent on the modulation of arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
- the methods and uses of the present invention may be desirably employed in humans, although animal treatment is also encompassed by the methods and uses described herein.
- the methods and uses encompassed by the present invention may be applied in vivo or in vitro.
- FIG. 1 Stimulation of monocytes with TGF- ⁇ 1 , leads to a dose-dependent increase in adhesion to a monolayer of endothelial cells.
- FIG. 2 MAC-1 receptor expression on monocytes significantly increases upon TGF- ⁇ 1 , stimulation.
- FIG. 3 TGF ⁇ treatment of EC's causes no increase in ICAM or VCAM expression
- FIG. 4 TGF ⁇ 1 exerts no chemo-attractivity towards monocytes over a layer of smooth muscle cells.
- FIG. 5 Maximum migration of monocytes over a layer of endothelial cells is achieved after pre-stimulation with TGF ⁇ 1 and using MCP-1 for the chemo-attractive gradient.
- FIG. 6 : 6 a shows an infiltrating cell around a growing collateral artery in a control animal, expressing TGF ⁇ 1 .
- TGF ⁇ 1 is abundantly present around the growing collateral artery ( 6 b ).
- FIG. 7 Immunolabeling for Ki-67 (green) in growing collateral arteries in control and TGF ⁇ 1 treated animals. Nuclei are labelled red with 7-AAD. Notice higher levels of immunodetectable Ki-67 positive cells within or around growing collateral arteries in TGF ⁇ 1 treated rabbits as compared with control group.
- FIG. 8 Total number of visible collateral arteries is increased upon TGF ⁇ 1 treatment when quantified under stereoscopic viewing.
- FIG. 9 Collateral conductance, one week after ligation of the femoral artery in the rabbit, increases about sevenfold upon TGF ⁇ 1 treatment.
- Monocytes were isolated from buffy coats of healthy blood donors by density gradient centrifugation and elutriation as described previously (Neil et al., Eur J. Cell Biol. 2000).
- Human umbilical endothelial cells (HUVECs) were prepared according to the method of Jaffe et al.(J. Clin. Invest. 52 (1973), 2745-2756) and were cultivated as described elsewhere (Neil et al., loc. cit.).
- Adhesion assays were performed as previously described (Neil et al., loc. cit.). Monocytes were stimulated for two hours with TGF- ⁇ 1 (concentrations, 0.01, 0.1, 1, 10 and 100 ng/ml) (PeproTech, London, UK) or LIPS (positive control). To identify the effects of TGF- ⁇ 1 stimulation of endothelial cells on the adhesion of monocytes, HUVECs were either stimulated with TNF- ⁇ (positive control, 10 ng/ml, Sigma, Deisenhofen, FRG) or with different doses of TGF- ⁇ 1 .
- Transmigration assays were performed as previously described (Neil et. al., loc. cit.) to test the chemoattractive potency of TGF- ⁇ 1 over a layer of endothelial cells.
- the influence of monocyte-stimulation and/or endothelium-stimulation with TGF- ⁇ 1 was determined.
- a strongly increased adhesion to the HUVEC layer was observed after stimulation of monocytes with TGF- ⁇ 1 .
- the adhesion of monocytes was linearly related to TGF- ⁇ 1 dose ( FIG. 1 ).
- the treatment of the HUVECs layer with TGF- ⁇ 1 caused no increase in the number of adhered monocytes as compared to the control. This was confirmed by FACS analysis, showing no significant increase in the expression of either ICAM, VCAM or P-selectin on endothelial cells treated with TGF- ⁇ 1 ( FIG. 3 ).
- TGF- ⁇ 1 showed no chemoattractive potency towards monocytes in the trans-endothelial migration assays.
- TGF- ⁇ 1 was diluted at different concentrations into the lower chamber of the assay, the migration of monocytes did not differ significantly from the control assay and was significantly lower as compared to MCP-1 ( FIG. 4 ).
- the HUVEC-layer was stimulated with TGF- ⁇ 1 , no increase in the number of transmigrated cells was observed.
- monocytes were pre-stimulated with TGF- ⁇ 1 an increased trans-endothelial migration of monocytes was observed as compared to the control group.
- X-ray angiograms were performed as previously described (Longland, Ann. Roy. Coll. Surg. Engl. 13 (1953), 161-164). Following Longland's definition, only vessels showing a defined stem, midzone and re-entry, identifying them as collateral arteries, were counted (Longland, loc. cit.). Hemodynamic measurements and calculations of collateral conductance were performed as previously described (Hoefer et. al., accepted for publication, Cardiovascular Research, 2001) using fluorescent microspheres and FACS-analysis.
- TGF- ⁇ 1 TGF- ⁇ 1
- PBS PBS
- TGF- ⁇ 1 TGF- ⁇ 1
- TGF-beta-1 Three days after ligation of the femoral artery, increased levels of TGF-beta-1 were noted within and around growing collateral arteries ( FIG. 6A ) whereas in tissue shown). The level of immunodetectable TGF- ⁇ 1 was conspicuously increased within and around growing collateral arteries in TGF- ⁇ 1 treated animals ( FIG. 6B ). Immunolabeling for Ki-67 revealed higher numbers of proliferating cells in growing collateral arteries after TGF- ⁇ 1 infusion as compared with the non-treated control group ( FIG. 7 ).
- Angiograms performed one week after ligation of the femoral artery showed several, typically corkscrewed, collateral arteries spanning from the arteria profunda femoris and the arteria circumflexa femoris to the arteria genualis and the arteria saphena parva.
- TGF- ⁇ 1 infusion for a time-period of one week had significantly increased the number of visible collateral arteries as compared to the PBS-control group ( FIG. 8 ; total number of visible collateral arteries: PBS; 15.2 ⁇ 3.4, TGF- ⁇ 1 ; 24.6 ⁇ 4.1, p ⁇ 0.05).
- One week after femoral artery ligation collateral conductance in the control group was 4.1 ⁇ 0.5 ml/min/100 mmHg.
- a conductance value of 161.5 ⁇ 10.8 ml/min/100 mmHg was measured.
- TGF ⁇ 1 is capable of mediating arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections by activation of the moncyte/macrophage pathway. This activation is accompanied by expression of the adhesion receptor Mac-1. Due to the experiments referred to above, the present invention provides novel means and methods for the treatment of disease by modulation of arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
Abstract
The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an organ, tissue or cells with transforming growth factor beta 1 (TGFβ1) or a nucleic acid molecule encoding TGFβ1. The present invention also relates to a method for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGFβ1.
Description
- This is a continuation of U.S. patent application Ser. No. 09/805,432, filed Mar. 14, 2001, now abandoned, the contents of which are incorporated herein, in their entirety, by reference.
- The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an organ, tissue or cells with transforming growth factor beta 1 (TGFβ1) or a nucleic acid molecule encoding TGFβ1. The present invention also relates to the use of TGFβ1 or a nucleic acid molecule encoding TGFβ1 for the preparation of pharmaceutical compositions for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Furthermore, the present invention relates to a method for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGFβ1. The present invention further involves the use of an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGFβ1 for the preparation of pharmaceutical compositions for the treatment of tumors.
- Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated herein by reference; however, there is no admission that any document cited is indeed prior art as to the present invention.
- In the treatment of subjects with arterial occlusive diseases most of the current treatment strategies aim at ameliorating their effects. The only curative approaches involve angioplasty (balloon dilatation) or bypassing surgery. The former carries a high risk of restenosis and can only be performed in certain arterial occlusive diseases, like ischemic heart disease. The latter is invasive and also restricted to certain kinds of arterial occlusive diseases. There is no established treatment for the enhancement of arteriogenesis and/or collateral growth.
- Vascular growth in adult organisms proceeds via two distinct mechanisms, sprouting of capillaries (angiogenesis) and in situ enlargement of preexisting arteriolar connections into true collateral arteries (Schaper, J. Collateral Circulation—Heart, Brain, Kidney, Limbs. Boston, Dordrecht, London: Kluwer Academic Publishers; 1993). Recent studies have disclosed mechanisms leading to angiogenesis with vascular endothelial growth factor (VEGF) as a major component (Tuder, J. Clin. Invest. 95 (1995), 1798-1807; Plate, Nature 359 (1992), 845-848; Ferrara, Endocrine Reviews 13 (1992), 18-42; Klagsbrun, Annu. Rev. Physiol. 53 (1991), 217-239; Leung, Science 246 (1990), 1306-1309). This specific endothelial mitogen is upregulated by hypoxia and is able to promote vessel growth when infused into rabbit hindlimbs after femoral artery excision (Takeshita, J. Clin. Invest. 93 (1994), 662-670; Bauters, Am. J. Physiol. 267 (1994), H1263-H1271). These studies however did not distinguish between capillary sprouting, a mechanism called angiogenesis, and true collateral artery growth. Whereas VEGF is only mitogenic for endothelial cells, collateral artery growth requires the proliferation of endothelial and smooth muscle cells and pronounced remodeling processes occur (Schaper, J. Collateral Circulation—Heart, Brain, Kidney, Limbs. Boston, Dordrecht, London: Kluwer Academic Publishers; 1993; Jakeman, J. Clin. Invest. 89 (1992), 244-253; Peters, Proc. Natl. Acad. Sci. USA 90 (1993), 8915-8919; Millauer, Cell 72 (1993), 835-846; Pasyk, Am. J. Physiol. 242 (1982), H1031-H1037). Furthermore mainly capillary sprouting is observed in ischemic territories for example in the pig heart or in rapidly growing tumors (Schaper, J. Collateral Circulation—Heart, Brain, Kidney, Limbs. Boston, Dordrecht, London: Kluwer Academic Publishers; 1993; Plate, Nature 359 (1992), 845-848; Bates, Curr. Opin. Genet. Dev. 6 (1996), 12-19; Bates, Curr. Opin. Genet. Dev. 6 (1996), 12-19; Gorge, Basic Res. Cardiol. 84 (1989), 524-535). True collateral artery growth, however, is temporally and spacially dissociated from ischemia in most models studied (Schaper, J. Collateral Circulation—Heart, Brain, Kidney, Limbs. Boston, Dordrecht, London: Kluwer Academic Publishers; 1993; Paskins-Hurlburt, Circ. Res. 70 (1992), 546-553). Other or additional mechanisms as those described for angiogenesis in ischemic territories are therefore needed to explain collateral artery growth. From previous studies it is known that these collateral arteries grow from preexisting arteriolar connections (Schaper, J. Collateral Circulation—Heart, Brain, Kidney, Limbs. Boston, Dordrecht, London: Kluwer Academic Publishers; 1993).
- However, while agents such as VEGF and other growth factors are presently being employed to stimulate the development of angiogenesis after arterial occlusion, such agents are not envisaged as being capable of modulating the growth of preexisting arteriolar connections into true collateral arteries.
- Thus, the technical problem of the present invention is to provide means and methods for the modulation of arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
- The solution to this technical problem is achieved by providing the embodiments characterized in the claims.
- Accordingly, the present invention is a method for enhancing arteriogenesis and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with transforming growth factor beta 1 (TGFβ1) and/or a nucleic acid molecule encoding said TGFβ1.
- In the context of this invention the term “transforming
growth factor beta 1” or “TGFβ1” refers to proteins and peptides which act on macrophages and which are capable of promoting collateral artery growth by direct activation, proliferation and/or potentiation of the effector functions of resident and newly recited macrophages on blood vessels. The present invention also comprises substances which are functionally equivalent to TGFβ1 in that these substances are capable of electing the aforementioned biological responses. The action of the TGFβ1 employed in the present invention may not be limited to the above-described specificity but they may also act on, for example eosinophils, lymphocyte subpopulations and/or stem cells. - In accordance with the present invention, a strong arteriogenic effect was found upon exogenous application of TGF-β1, in vivo after femoral artery ligation. The number of collateral arteries on the x-ray angiograms as well as the conductance of the collateral vessels showed a significant increase upon TGF-β1, treatment. In-vitro experiments showed activation and adhesion of monocytes which were accompanied by upregulation of the moncyte/macrophage adhesion receptor Mac-1 but no chemo-attractive activity of TGF-β1over a layer of endothelial cells.
- The in-vivo arteriogenic effects of TGF-β1, observed in accordance with the present invention are caused by activation of monocytes, leading to an increased adhesion, migration and subsequently perivascular accumulation of monocytes/macrophages. It has been found in accordance with the invention that said adhesion is inter alia due to increased expression of the adhesion receptor Mac-1. Adhesion and transmigration of monocytes/macrophages are initial steps in the process of arteriogenesis. In a further step production of various growth factors, such as basic-fibroblast growth factor (b-FGF), Platlet derived growth factor (PDGF). tumor necrosisi factor alpha (TNFa), Interleukine 1 (II-1), Interleukine 6 (IL-6) or vascular endothelial growth factor (VEGF) is stimulated in or by said monocytes/macrophages. Moreover, arteriogenesis is also effected by direct stimulation of vascular smooth muscle cells and/or endothelial cells by TGF-β1. Thus, in addition to the initiation of arteriogenesis due to the stimulation of the monocyte/macrophage pathway, arteriogenesis is further influenced by TGF-β1 due to the direct stimulation of the vascular smooth muscle cells and/or the endothelial cells in accordance with the present invention.
- To the best of the inventor's knowledge, this is the first report disclosing TGF-β1, as a third specific arteriogenic substance, next to MCP-1 and the aforementioned CSFs, acting via the monocytic pathway, wherein TGF-β1, increases arteriogenesis via activation of monocytes and induction of MAC-1 expression.
- Advantageously, macrophages/monocytes can be efficiently activated by TGFβ1 and can subsequently adhere due to the upregulation of Mac-1 expression. Thereby, arteriogenesis via the macrophage/monocyte pathway is initiated and can be efficiently simulated in vivo.
- The TGFβ1 to be employed in the methods and uses of the present invention may be obtained from various sources described in the prior art; see, e.g., Klagsbrun, Annu. Rev. Physiol. 53 (1991), 217-239. The potential exists, in the use of recombinant DNA technology, for the preparation of various derivatives of TGFβ1 comprising a functional part thereof or proteins which are functionally equivalent to TGFβ1. In this context, as used throughout this specification “functional equivalent or “functional part” of TGFβ1 means a protein having part or all of the primary structural conformation of TGFβ1 possessing at least the biological property of promoting at least one macrophage or granulocyte effector function mentioned above. The functional part of said protein or the functionally equivalent protein may be a derivative by way of amino acid deletion(s), substitution(s), insertion(s), addition(s) and/or replacement(s) of the amino acid sequence, for example by means of site directed mutagenesis of the underlying. DNA. Recombinant DNA technology is well known to those skilled in the art and described, for example, in Sambrook et al. (Molecular cloning; A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y. (1989)). Modified CSFs art described, e.g., in Yamasaki, Journal of Biochemistry 115 (1994), 814-819.
- TGFβ1 or functional parts thereof or proteins which are functionally equivalent thereto, may be produced by known conventional chemical syntheses or recombinant techniques employing the amino acid and DNA sequences described in the prior art; see, e.g., EP-A-0 177 568; Han, Source Gene 175 (1996), 101-104; Kothari, Blood Cells, Molecules & Diseases 21 (1995), 192-200; Holloway. European Journal of Cancer 30A (1994), 2-6. For example, TGFβ1 may be produced by culturing a suitable cell or cell line which has been transformed with a DNA sequence encoding upon expression under the control of regulatory sequences TGFβ1 or a functional part thereof or a protein which is functionally equivalent TGFβ1. Suitable techniques for the production of recombinant proteins are described in, e.g., Sambrook, supra. Methods for constructing TGFβ1 and proteins as described above useful in the methods and uses of the present invention by chemical synthetic means are also known to those of skill in the art.
- In another embodiment the invention relates to the use of transforming growth factor beta 1 (TGFβ1) and/or a nucleic acid molecule encoding said T TGFβ1 for the preparation of a pharmaceutical composition for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
- The pharmaceutical composition comprises at least TGFβ1 as defined above, and optionally a pharmaceutically acceptable carrier or exipient. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by conventional methods. The pharmaceutical compositions can be administered to the subject at a suitable dose. The dosage regimen may be determined by the attending physician considering the condition of the patient, the severity of the disease and other clinical factors. Administration of the suitable compositions may be effected by different ways, e.g. by intravenous, intraperetoneal, subcutaneous, intramuscular, topical or intradermal administration. The dosage regimen will be determined by the attending physician and other clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Generally, the regimen as a regular administration of the pharmaceutical composition should be in the range of 1 μg to 10 mg units per day. If the regimen is a continuous infusion, it should also be in the range of 1 μg to 10 mg units per kilogram of body weight per minute, respectively. Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 106 to 1012 copies of the DNA molecule. The compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery.
- In a preferred embodiment, TGFβ1 used in the methods and uses of the invention is a recombinant TGFβ1. DNA sequences for TGFβ1 which can be applied in the methods and uses of the invention are known in the prior art and described in e.g. Ohta, Biochem. J. 350 (2000), 395-404. Moreover, DNA and amino acid sequences of TGFβ1 are available in the Gene Bank database. As described above, methods for the production of recombinant proteins are well-known to the person skilled in the art; see, e.g., Sambrook, supra.
- In a further preferred embodiment, the method and the use of the present invention is designed to be applied in conjugation with a growth factor or cytokine comprising fibroblast growth factor (FGF), preferably b-FGF, platelet derived growth factor (PDGF), tumor necrosis Factor alpha (TNFα), interleukin 1 (IL-1), Interleukin 6 (IL-6), or vascular endothelial growth factor (VEGF). This embodiment is particularly suited for enhancing of both sprouting of capillaries (angiogenesis) and in situ enlargement of preexisting arteriolar connections into true collateral arteries. Pharmaceutical compositions comprising TGFβ1, and a growth factor such as VEGF may be used for the treatment of peripheral vascular diseases or coronary artery disease.
- The nucleic acid and amino acid sequences of said growth factors or cytokines are well known in the art and are available e.g. in the GeneBank database.
- In another preferred embodiment, the method of the invention comprises
-
- (a) obtaining cells, tissue or an organ from a subject; (b) introducing into said cells, tissue or organ a nucleic acid molecule encoding and capable of expressing the TGFβ1 in vivo; and
- (c) reintroducing the cells, tissue or organ obtained in step (b) into the same subject or a different subject.
- It is envisaged by the present invention that the TGFβ1 and the nucleic acid molecules encoding said proteins are administered either alone or in combination, and optionally together with a pharmaceutically acceptable carrier or exipient. Said nucleic acid molecules may be stably integrated into the genome of the cell or may be maintained in a form extrachromosomally, see, e.g., Calos, Trends Genet. 12 (1996), 463-466. On the other hand, viral vectors described in the prior art may be used for transfecting certain cells, tissues or organs.
- Furthermore, it is possible to use a pharmaceutical composition of the invention which comprises a nucleic acid molecule encoding TGFβ1 in gene therapy. Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, r naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses, and adeno-associated viruses, among others. Delivery of nucleic acid molecules to a specific site in the body for gene therapy may also be accomplished using a biolistic delivery system, such as that described by Williams (Proc. Nati. Acad. Sci. USA 88 (1991), 2726-2729).
- Standard methods for transfecting cells with nucleic acid molecules are well known r to those skilled in the art of molecular biology, see, e.g., WO 94/29469. Gene therapy to prevent or decrease the development of diseases described herein may be carried out by directly administering the nucleic acid molecule encoding TGFβ1 to r a patient or by transfecting cells with said nucleic acid molecule ex vivo and infusing the transfected cells into the patient. Furthermore, research pertaining to gene transfer into cells of the germ line is one of the fastest growing fields in reproductive biology. Gene therapy, which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Suitable vectors and methods for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in, the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Isner, Lancet 348 (1996). 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Wang, Nature Medicine 2 (1996), 714-716; W094/29469; WO 97/00957 or Schaper, Current Opinion in Biotechnology 7 (1996), 635-640, and references cited therein. The nucleic acid molecules comprised in the pharmaceutical composition of the invention may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) containing said nucleic acid molecule into the cell. Preferably, said cell is a germ line cell, embryonic cell, or egg cell or derived therefrom.
- It is to be understood that the introduced nucleic acid molecules encoding the TGFβ1 express said proteins after introduction into said cell and preferably remain in this status during the lifetime of said cell. For example, cell lines which stably express said TGFβ1 may be engineered according to methods well known to those skilled in the art. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with the recombinant DNA molecule or vector of the invention and a selectable marker, either on the same or separate vectors. Following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows for the selection of cells having stably integrated the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express TGFβ1. Such cells may be also be administered in accordance with the pharmaceutical compositions, methods and uses of the invention.
- A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, Cell 11 (1977), 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska, Proc. Natl. Acad. Sci. USA 48 (1962). 2026), and adenine phosphoribosyltransferase (Lowy, Cell 22 (1980), 817) in tk_. hgprt or aprt cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, Proc. Nati. Acad. Sci. USA 77 (1980), 3567; O'Hare, Proc. Natl. Acad. Sci. USA 78 (1981), 1527), gpt, which confers resistance to mycophenolic acid (Mulligan, Proc. Natl. Acad. Sci. USA 78 ; (1981), 2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, J. Mol. Biol. 150 (1981), 1); hygro, which confers resistance to hygromycin (Santerre, Gene 30 (1984), 147); or puromycin (pat, puromycin N-acetyl transferase). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman, Proc. Natl. Acad. Sci. USA 85 (1988), 8047); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue, 1987, In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed.).
- Thus, in a preferred embodiment, the nucleic acid molecule comprised in the pharmaceutical composition for the use of the invention is designed for the expression of TGFβ1 by cells in vivo by, for example, direct introduction of said nucleic acid, molecule or introduction of a plasmid, a plasmid in liposomes, or a viral vector (e.g. adenoviral, retroviral) containing said nucleic acid molecule.
- In a preferred embodiment of the method and uses of the present invention, the TGFβ1 derivative or functional equivalent substance is an antibody, (poly)peptide, nucleic acid, small organic compound, ligand, hormone, PNA or peptidomimetic.
- In this context, it is understood that TGFβ1 to be employed according to the present invention may be, e.g., modified by conventional methods known in the art. For example, it is possible to use fragments which retain the biological activity of TGFβ1 as k described above, namely the capability of promoting collateral artery growth. This further allows the construction of chimeric proteins and peptides wherein other functional amino acid sequences may be either physically linked by, e.g., chemical means to TGFβ1 or may be fused by recombinant DNA techniques well known in the art. Furthermore, folding simulations and computer redesign of structural motifs of the C TGFβ1 as well as their respective receptors can be performed using appropriate computer programs (Olszewski, Proteins 25 (1996), 286-299; Hoffman, Comput. Appl. 11 Biosci. 11 (1995), 675-679). Computer modeling of protein folding can be used for the conformational and energetic analysis of detailed receptor and protein models (Monge, J. Mol. Biol. 247 (1995), 995-1012; Renouf, Adv. Exp. Med. Biol. 376 (1995), 37-45). In particular, the appropriate programs can be used for the identification of interactive sites of TGFβ1 and their respective receptors by computer assistant searches for complementary peptide sequences (Fassina, Immunomethods 5 (1994), 114-120). Further appropriate computer systems for the design of protein and peptides are described in the prior art, for example in Berry, Biochem. Soc. Trans. 22 (1994), 10331036; Wodak, Ann. N. Y. Acad. Sci. 501 (1987), 1-13; Pabo, Biochemistry 25 (1986), 5987-5991. The results obtained from the above-described computer analysis can be used for, e.g., the preparation of peptidomimetics of TGFβ1, or fragments thereof. Such pseudopeptide analogues of the natural amino acid sequence of the protein may very efficiently mimic the parent protein or peptide (Benkirane, J. Biol. Chem. 271 (1996), 33218-33224). For example, incorporation of easily available achiral Q-amino acid residues into TGFβ1 protein or a fragment thereof results in the substitution of amide bonds by polymethylene units of an aliphatic chain, thereby providing a convenient strategy for constructing a peptidomimetic (Banerjee, Biopolymers 39 (1996), 769-777). Superactive peptidomimetic analogues of small peptide hormones in other systems are described in the prior art (Zhang, Biochem. Biophys. Res. Commun. 224 (1996), 327-331). Appropriate peptidomimetics may also be identified by the synthesis of peptidomimetic combinatorial libraries through successive amide alkylation and testing the resulting compounds, e.g., according to the methods described in the prior art. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, Methods in Enzymology 267 (1996), 220-234 and Domer, Bioorg. Med. Chem. 4 (1996), 709-715. Furthermore, antibodies or fragments thereof may be employed which, e.g., upon binding to a TGFβ1-receptor mimic the biological activity of the receptor's ligand.
- Furthermore, a three-dimensional and/or crystallographic structure of the TGFβ1 or of its receptors can be used for the design of peptidomimetic inhibitors of the biological activity of a CSF (Rose, Biochemistry 35 (1996), 12933-12944; Rutenbar, Bioorg. Med. Chem. 4 (1996), 1545-1558).
- In a preferred embodiment, the methods and uses of the invention may be employed for diseases caused by a vascular disease or a cardiac infarct or a stroke or for any disease where an increase of blood supply via collaterals, arteries etc. is needed.
- In a particularly preferred embodiment, the methods and uses of the invention are designed to be applied to a subject suffering from arteriosclerosis, a coronary artery disease, a cerebral occlusive disease, a peripheral occlusive disease, a visceral occlusive disease, renal occlusive disease, a mesenterial arterial insufficiency or an ophthamic or retenal occlusion or for any disease where atherosclerotic plaques in the vascular wall lead to an obstruction of the vessel diameter.
- In a further preferred embodiment, the methods and uses of the invention are designed to be applied to a subject during or after exposure to an agent or radiation or surgical treatment which damage or destroy arteries.
- As discussed above, arteriogenesis and the growth of arteries from preexisting arteriolar connections is essential for the delivery of nutrition to tumors. Thus, if the growth of said vessels to the tumor would be suppressed suppression and/or inhibition of tumor growth is to be expected.
- Accordingly, the invention relates to a method for the treatment of tumors comprising contacting organs, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections though inhibition of the biological activity of TGFβ1 as defined above.
- The explanations and definitions of the terms herein above apply mutatis mutandis to the aforementioned method and the following method and use claims.
- As discussed above, macrophages play a pivotal role during arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. TGFβ1 stimulates macrophages/monocytes and increases adhesion of said cells to the enothelial cells of the blood vessels inter alia via increased expression of the adhesion receptor Mac-1. Transmigration and adhesion to the endothelial cells are the initial steps of arteriogenesis as occurs during tumor formation. In a further step, growth factors and cytokines comprising those referred to herein above are released due to said stimulation of the macrophages/monocytes by TGFβ1. As is evident from the above, by inhibition of TGFβ1 arteriogenesis can be efficiently suppressed at the initial steps and tumor formation and progression is inhibited.
- Advantageously, by identifying TGFβ1 as a trigger molecule in accordance with the present invention it is now possible to treat tumor diseases caused or influenced by arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections by the methods and uses referred to herein above and below.
- Moreover, the invention relates to the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGFβ1 as defined above for the preparation of a pharmaceutical composition for the treatment of tumors.
- In a more preferred embodiment of the method or use of the invention the agent inhibits the biological activity of TGFβ1 and/or inhibits an intracellular signal or signal cascade comprising SMAD proteins triggered in macrophages through the receptor for TGFβ1.
- The term “SMAD” proteins used in accordance with the present invention refers to a family of signal transducers and transcription factors which are activated intracellularly by the TGFP receptors upon stimulation by TGFβ1. These signal transducers are either directly or indirectly involved in the activation of TGFβ1 target genes and hence in elicting a biological response. Thus, the expression of growth factors or Mac1 protein may be stimulated and/or induced by said SMAD proteins.
- An agent which inhibits the biological activity of TGFβ1 also inhibits the intracellular i transducing of the signal by SMAD proteins upon binding of TGFβ1 to its receptor on target cells.
- SMAD proteins are well known in the art. Nucleic acid or amino acid sequences are available, e.g., in the database GeneBank. Moreover, it has been reported that blood vessels are a pivotal expression site of said SMAD proteins in the developing mouse embryo (Dick, Developmental Dynamics, 211 (1998), 293-305).
- In a more preferred embodiment of the use of the invention, the agent blocks interaction of TGFβ1 and its receptor.
- Receptors for TGFβ1 are well known in the art and have been described in, e.g., Lin et al., Mol. Reprod. Dev. 32 (1992), 105-110; Nilsen-Hamilton et al., New Biol. 4 (1992), 127-131. Moreover, amino acid and nucleic acid sequences are provided by the Gene Bank database.
- In a preferred embodiment, the agent used in the methods and uses of the invention is a(n) antibody, (poly)peptide, nucleic acid, small organic compound, ligand, hormone, PNA or peptidomimetic.
- Nucleic acid molecules specifically hybridizing to TGFβ1 encoding genes and/or their regulatory sequences may be used for repression of expression of said gene, for example due to an antisense or triple helix effect or they may be used for the construction of appropriate ribozymes (see, e.g., EP-
B1 0 291 533, EP-A1 0 321 201, EP-A2 0 360 257) which specifically cleave the (pre)-mRNA of a gene encoding a CSF. The nucleic and amino acid sequences encoding TGFβ1 are known in the art and described, for example, in Han, Source Gene 175 (1996), 101-104; Kothari, Blood Cells, Molecules & Diseases 21 (1995), 192-200 or in Holloway, European Journal of Cancer 30A (1994), 2-6. Selection of appropriate target sites and corresponding ribozymes can be done as described for example in Steinecke, Ribozymes, Methods inCell Biology 50, Galbraith et al. eds Academic Press, Inc. (1995), 449-460. - Nucleic acids comprise DNA or RNA or hybrids thereof. Furthermore, said nucleic acid may contain, for example, thioester bonds and/or nucleotide analogues, commonly used in oligonucleotide anti-sense approaches. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell. Furthermore, the so-called “peptide nucleic acid” (PNA) technique can be used for the inhibition of the expression of a gene encoding a TGFβ1. For example, the binding of PNAs to complementary as well as various single stranded RNA and DNA nucleic acid molecules can be systematically investigated using, e.g., thermal denaturation and BlAcore surface-interaction techniques (Jensen, Biochemistry 36 (1997), 5072-5077). The synthesis of PNAs can be performed, according to methods known in the art, for example, as described in Koch, J. Pept. Res. 49 (1997), 80-88; Finn, Nucleic Acids Research 24 (1996), 3357-3363, TGFβ1 and its receptor can be performed as described above to design drugs capable of inhibiting the biological activity of TGFβ1.
- Furthermore, antibodies may be employed specifically recognizing TGFβ1 or its j receptor or parts, i.e. specific fragments or epitopes, of TGFβ1 and its receptor thereby j inactivating the TGFβ1 or its receptor. These antibodies can be monoclonal antibodies, polyclonal antibodies or synthetic antibodies as well as fragments of antibodies, such as Fab, Fv or scFv fragments etc. Antibodies or fragments thereof can be obtained by using methods which are described, e.g., in Harlow and Lane “Antibodies, A Laboratory Manual”, CSH Press, Cold Spring Harbor, 1988 or EP-
B1 0 451 216 and references cited therein. For example, surface plasmon resonance as employed in the BlAcore system can be used to increase the efficiency of phage antibodies which bind to an epitope of TGFβ1 or its receptor (Schier, Human I Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13). - Putative inhibitors which can be used in accordance with the present invention including peptides, proteins, nucleic acids, antibodies, small organic compounds, ligands, hormones, peptidomimetics, PNAs and the like capable of inhibiting the biological activity of TGFβ1 or its receptor may be identified according to the methods known in the art, for example as described in EP-A-O 403 506 or in the appended examples.
- In a preferred embodiment, methods and uses of the invention are employed for the treatment of a tumor which is a vascular tumor, preferably selected from the group consisting of Colon Carcinoma, Sarcoma, Carcinoma in the breast, Carcinoma in the head/neck, Mesothelioma, Glioblastoma, Lymphoma and Meningeoma.
- In a preferred embodiment, the pharmaceutical composition in the use of the invention is designed for administration by catheter intraarterial, intravenous, intraperitoneal or subcutenous routes. In the examples of the present invention the TGFβ1 protein was for instance administered locally via osmotic minipump.
- These and other embodiments are disclosed or are obvious from and encompassed by the description and examples of the present invention. Further literature concerning any one of the methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries, using for example electronic devices. For example the public database “Medline” may be utilized which is available on the Internet at the website of the National Library of Medicine, National Institutes of Health, Bethesda, Md., U.S.A. Further databases, such as databases at the websites of the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Md., U.S.A.; Centre de Resources, INFOBIOGEN, France; Friedrich Miescher Institute, Novartis Research Foundation, Basel, Switzerland; and The Institute for Genomic Research, Rockville, Md., U.S.A., are known to the person skilled in the art and can be obtained from the Internet. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is given in Berks, TIBTECH 12 (1994), 352-364.
- The use and methods of the invention can be used for the treatment of all kinds of diseases hitherto unknown as being related to or dependent on the modulation of arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. The methods and uses of the present invention may be desirably employed in humans, although animal treatment is also encompassed by the methods and uses described herein. Moreover, the methods and uses encompassed by the present invention may be applied in vivo or in vitro.
- The figures show
-
FIG. 1 : Stimulation of monocytes with TGF-β1, leads to a dose-dependent increase in adhesion to a monolayer of endothelial cells. -
FIG. 2 : MAC-1 receptor expression on monocytes significantly increases upon TGF-β1, stimulation. -
FIG. 3 : TGFβ treatment of EC's causes no increase in ICAM or VCAM expression -
FIG. 4 : TGFβ1 exerts no chemo-attractivity towards monocytes over a layer of smooth muscle cells. -
FIG. 5 : Maximum migration of monocytes over a layer of endothelial cells is achieved after pre-stimulation with TGFβ1 and using MCP-1 for the chemo-attractive gradient. -
FIG. 6 : 6 a shows an infiltrating cell around a growing collateral artery in a control animal, expressing TGFβ1. In the treated animal, TGFβ1 is abundantly present around the growing collateral artery (6 b). -
FIG. 7 : Immunolabeling for Ki-67 (green) in growing collateral arteries in control and TGFβ1 treated animals. Nuclei are labelled red with 7-AAD. Notice higher levels of immunodetectable Ki-67 positive cells within or around growing collateral arteries in TGFβ1 treated rabbits as compared with control group. -
FIG. 8 : Total number of visible collateral arteries is increased upon TGFβ1 treatment when quantified under stereoscopic viewing. -
FIG. 9 : Collateral conductance, one week after ligation of the femoral artery in the rabbit, increases about sevenfold upon TGFβ1 treatment. - The examples illustrate the invention.
- Monocytes were isolated from buffy coats of healthy blood donors by density gradient centrifugation and elutriation as described previously (Neil et al., Eur J. Cell Biol. 2000). Human umbilical endothelial cells (HUVECs) were prepared according to the method of Jaffe et al.(J. Clin. Invest. 52 (1973), 2745-2756) and were cultivated as described elsewhere (Neil et al., loc. cit.).
- Adhesion assays were performed as previously described (Neil et al., loc. cit.). Monocytes were stimulated for two hours with TGF-β1 (concentrations, 0.01, 0.1, 1, 10 and 100 ng/ml) (PeproTech, London, UK) or LIPS (positive control). To identify the effects of TGF-β1 stimulation of endothelial cells on the adhesion of monocytes, HUVECs were either stimulated with TNF-α (positive control, 10 ng/ml, Sigma, Deisenhofen, FRG) or with different doses of TGF-β1.
- Transmigration assays were performed as previously described (Neil et. al., loc. cit.) to test the chemoattractive potency of TGF-β1 over a layer of endothelial cells. In a second set of transmigration assays the influence of monocyte-stimulation and/or endothelium-stimulation with TGF-β1 was determined.
- A strongly increased adhesion to the HUVEC layer was observed after stimulation of monocytes with TGF-β1. The adhesion of monocytes was linearly related to TGF-β1 dose (
FIG. 1 ). The maximally achieved adhesion of monocytes upon TGF-β1 treatment was similar to the adhesion observed for the positive control (LPS: 120.2±8.3 cells/field vs. TGF-β1: 114.0±4.7, p=NS). The treatment of the HUVECs layer with TGF-β1 caused no increase in the number of adhered monocytes as compared to the control. This was confirmed by FACS analysis, showing no significant increase in the expression of either ICAM, VCAM or P-selectin on endothelial cells treated with TGF-β1 (FIG. 3 ). - TGF-β1 showed no chemoattractive potency towards monocytes in the trans-endothelial migration assays. When TGF-β1 was diluted at different concentrations into the lower chamber of the assay, the migration of monocytes did not differ significantly from the control assay and was significantly lower as compared to MCP-1 (
FIG. 4 ). Also when the HUVEC-layer was stimulated with TGF-β1, no increase in the number of transmigrated cells was observed. However, when monocytes were pre-stimulated with TGF-β1 an increased trans-endothelial migration of monocytes was observed as compared to the control group. When monocytes and endothelium were stimulated simultaneously with TGF-β1 the transmigration rate was similar to that after monocyte stimulation alone. Maximum migration of monocytes was f achieved when MCP-1 was added to the lower chamber of the transmigration assay, in combination with TGF-β1 stimulation of monocytes (FIG. 5 ). - The expression of the MAC-1 receptor significantly increased, dose-dependently, after stimulation of human monocytes with TGF-β1 (
FIG. 2 ). A similar dose dependent response of MAC-1 expression (CD11b/CD18) upon TGF-β1 stimulation was found in rabbit monocytes (control: 91.2±4.2/482±21.7; TGF-β 1 50 ng/ml: 129,3±318/553,3 ±17,9;TGFβ 1100 ng/ml: 155.5±7.2/602.2±23.4; TGF-β 1 200 ng/ml 193.9±6.7/675.5±25.7, p<0.05 for all differences). - 36 New Zealand White Rabbits (NZWR) were randomly assigned to one of three groups (n=12 each). In two groups the femoral artery was ligated and either Phosphate Buffered Saline (PBS) or TGF-β1 (0.48 μg/kg/d) (PeproTech, London, UK) was delivered locally, directly into the collateral circulation, via an osmotic minipump as previously described (Hoefer et. al., accepted for publication, Cardiovascular Research, 2001). To obtain the normal conductance value and angiographic appearance of the vascular tree of the rabbit hindlimb, the third group was evaluated without ligation. For final experiments animals of each group were randomly assigned to either angiographic or hemodynamic measurements. X-ray angiograms were performed as previously described (Longland, Ann. Roy. Coll. Surg. Engl. 13 (1953), 161-164). Following Longland's definition, only vessels showing a defined stem, midzone and re-entry, identifying them as collateral arteries, were counted (Longland, loc. cit.). Hemodynamic measurements and calculations of collateral conductance were performed as previously described (Hoefer et. al., accepted for publication, Cardiovascular Research, 2001) using fluorescent microspheres and FACS-analysis.
- An additional six animals were operated as described above and treated with either PBS (n=3) or TGF-β1 (n=3). Three days after ligation of the femoral artery animals were sacrificed and tissue was harvested from the hindlimb muscles for histological examination. For the rate of proliferation, sections were stained with Ki-67 (Monotec, mouse derived). Alpha-smooth muscle actin was detected using FITC-conjugated alpha-SM antibody (clone 1A4, Sigma). For the detection of TGF-β1 around the growing collateral arteries a mouse-derived TGF-β1 antibody was used (clone MAB 240, R&D systems). TOTO-3 and 7-aminoactinomycin D (Molecular Probes) were used for nuclear staining. Tissue samples were examined by CSLM using Leica TCSNT, equipped with argon/krypton and helium/neon lasers.
- Significant differences between sample means were determined with a two-tailed Student's T-test. Differences with a p-value<0.05 were classified as significant.
- No animals were lost during or after femoral artery ligation. Gangrene or gross impairment of hindlimb function after femoral artery occlusion was also not observed. The body weights and body temperature within the different groups did not show any significant difference. There were no detectable differences in the values of total protein, albumin, glutamic oxaloacetic transaminase and glutamic pyruvic transaminase.
- Three days after ligation of the femoral artery, increased levels of TGF-beta-1 were noted within and around growing collateral arteries (
FIG. 6A ) whereas in tissue shown). The level of immunodetectable TGF-β1 was conspicuously increased within and around growing collateral arteries in TGF-β1 treated animals (FIG. 6B ). Immunolabeling for Ki-67 revealed higher numbers of proliferating cells in growing collateral arteries after TGF-β1 infusion as compared with the non-treated control group (FIG. 7 ). - Angiograms performed one week after ligation of the femoral artery showed several, typically corkscrewed, collateral arteries spanning from the arteria profunda femoris and the arteria circumflexa femoris to the arteria genualis and the arteria saphena parva. TGF-β1 infusion for a time-period of one week had significantly increased the number of visible collateral arteries as compared to the PBS-control group (
FIG. 8 ; total number of visible collateral arteries: PBS; 15.2±3.4, TGF-β1; 24.6±4.1, p<0.05). One week after femoral artery ligation collateral conductance in the control group was 4.1±0.5 ml/min/100 mmHg. TGF-β1 had significantly increased collateral conductance to over 6-fold as compared to the PBS-treated group (25.6±3.7=ml/min/100 mmHg,FIG. 9 ). In the non-occluded control group a conductance value of 161.5±10.8 ml/min/100 mmHg was measured. - The results of the experiments performed in accordance with the present invention indicate that TGFβ1 is capable of mediating arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections by activation of the moncyte/macrophage pathway. This activation is accompanied by expression of the adhesion receptor Mac-1. Due to the experiments referred to above, the present invention provides novel means and methods for the treatment of disease by modulation of arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections.
- The present invention is not to be limited in scope by its specific embodiments described which are intended as single illustrations of individual aspects of the invention and any proteins, nucleic acid molecules, or compounds which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those shown and described therein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Said modifications intended to fall within the scope of the appended claims. Accordingly, having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.
Claims (12)
1. A method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising an organ or tissue having preexisting arteriolar connections with transforming growth factor beta 1 (TGFβ1) administered intra-arterially, wherein said TGFβ1 is a polypeptide.
2. (canceled)
3. The method of claim 1 , wherein the TGFβ1 is a recombinant TGFβ1.
4. The method of claim 1 , further comprising contacting the organ or tissue with a growth factor or cytokine.
5. (canceled)
6. The method of claim 4 , wherein said growth factor or cytokine is b-FGF, PDGF, TNF-α, IL-1, IL-6 or VEGF.
7-9. (canceled)
10. The method of claim 1 wherein said method is applied to a subject suffering from a vascular disease or a cardiac infarct or a stroke.
11. The method of claim 10 , wherein said vascular disease is arteriosclerosis and/or a hyperlipidemic condition, a coronary artery disease, cerebral occlusive disease, peripheral occlusive disease, visceral occlusive disease, renal artery disease, mesenterial arterial insufficiency or an ophthalmic or retinal occlusion.
12. The method of claim 1 , wherein said method is applied to a subject during or after exposure to an agent or radiation or surgical treatment which damages or destroys arteries.
13-21. (canceled)
22. The method of claim 1 , wherein the transforming growth factor beta 1 is delivered directly to said organ or tissue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/252,623 US20060073128A1 (en) | 2001-03-14 | 2005-10-19 | Means and methods for the modulation of arteriogenesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/805,432 US20020131959A1 (en) | 2001-03-14 | 2001-03-14 | Means and methods for the modulation of arteriogenesis |
US11/252,623 US20060073128A1 (en) | 2001-03-14 | 2005-10-19 | Means and methods for the modulation of arteriogenesis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/805,432 Continuation US20020131959A1 (en) | 2001-03-14 | 2001-03-14 | Means and methods for the modulation of arteriogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060073128A1 true US20060073128A1 (en) | 2006-04-06 |
Family
ID=25191558
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/805,432 Abandoned US20020131959A1 (en) | 2001-03-14 | 2001-03-14 | Means and methods for the modulation of arteriogenesis |
US11/252,623 Abandoned US20060073128A1 (en) | 2001-03-14 | 2005-10-19 | Means and methods for the modulation of arteriogenesis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/805,432 Abandoned US20020131959A1 (en) | 2001-03-14 | 2001-03-14 | Means and methods for the modulation of arteriogenesis |
Country Status (1)
Country | Link |
---|---|
US (2) | US20020131959A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4891477B2 (en) * | 1997-10-02 | 2012-03-07 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. | Methods for the regulation of angiogenesis and / or development of side arteries and / or other arteries from existing arteriole networks |
WO2006109044A2 (en) * | 2005-04-11 | 2006-10-19 | Yale University | Selective modulation of tumour necrosis factor receptors in therapy |
EP1998797A1 (en) * | 2006-03-02 | 2008-12-10 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | Master gene of arteriogenesis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5482851A (en) * | 1985-03-22 | 1996-01-09 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
-
2001
- 2001-03-14 US US09/805,432 patent/US20020131959A1/en not_active Abandoned
-
2005
- 2005-10-19 US US11/252,623 patent/US20060073128A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5482851A (en) * | 1985-03-22 | 1996-01-09 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
Also Published As
Publication number | Publication date |
---|---|
US20020131959A1 (en) | 2002-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8101188B2 (en) | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections | |
US7045133B2 (en) | VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor | |
AU2002225265B2 (en) | VEGFR-3 Binding peptides and their use for inhibiting angiogenesis | |
US9289489B2 (en) | NOTCH inhibition in the treatment of cardiovascular disease | |
US20060003932A1 (en) | Method for promoting neovascularization | |
AU2001259519A1 (en) | Method for promoting neovascularization | |
US6592862B1 (en) | Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections | |
US20060073128A1 (en) | Means and methods for the modulation of arteriogenesis | |
EP1358888A1 (en) | The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis | |
JP2000510112A (en) | Use of prolactin as a TGF-β antagonist | |
JP2021525221A (en) | Anticoagulant proteins and their use to treat diseases associated with neutrophil activation | |
US9567396B2 (en) | Notch inhibition in the prevention of vein graft failure | |
WO1999061039A2 (en) | Novel composition for modulating ischemic cell death | |
WO2001052883A1 (en) | Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics | |
US9193800B2 (en) | Preparations and methods for treating malignancies | |
US20060275303A1 (en) | Modulating angiogenesis using LL-37/HCAP-18 | |
Marone et al. | Expression and Functions of the Vascular | |
ANTITHROMBIN III et al. | ENDOTHELIN B RECEPTORS ON HUMAN ENDOTHELIAL CELLS AND SMOOTH MUSCLE CELLS SHOW EQUIVALENT BINDING PHARMACOLOGY | |
JPH1059850A (en) | Platelet derived growth factor expression suppressor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |